Effect of High Dose Insulin on Infectious Complications Following Major Surgery
Launched by MCGILL UNIVERSITY HEALTH CENTRE/RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE · Feb 6, 2012
Trial Information
Current as of November 14, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether maintaining normal blood sugar levels with a special insulin treatment can help reduce the risk of infections after major abdominal surgeries, such as liver, pancreatic, and colorectal surgery. Researchers believe that keeping blood sugar stable during and after surgery might lower the chances of getting infections at the surgical site, which can be a common complication.
To participate in this study, individuals must be at least 18 years old and scheduled for elective liver, pancreatic, or colorectal surgery. They should also be able to give informed consent, meaning they understand the study and agree to take part. Participants in the trial can expect to receive insulin treatment during their hospital stay to help manage their blood sugar levels. This study is currently recruiting participants, and anyone interested should talk to their doctor for more information.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • \> 18 years old
- • elective liver, pancreatic or colorectal surgery
- • ability to give informed consent
- Exclusion Criteria:
About Mcgill University Health Centre/Research Institute Of The Mcgill University Health Centre
The McGill University Health Centre (MUHC) and the Research Institute of the McGill University Health Centre (RI-MUHC) are leading institutions in clinical research and healthcare innovation. With a commitment to advancing medical knowledge and improving patient outcomes, the MUHC integrates cutting-edge research with high-quality patient care. The RI-MUHC fosters a collaborative environment where multidisciplinary teams engage in transformative research across various fields, including oncology, neurology, and cardiovascular health. By leveraging state-of-the-art facilities and a robust network of clinical expertise, both entities strive to translate scientific discoveries into effective treatments, ultimately enhancing the quality of life for patients locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montreal, Quebec, Canada
Montreal, Quebec, Canada
Montreal, Quebec, Canada
Independencia, Santiago, Chile
Patients applied
Trial Officials
Ralph Lattermann, MD PhD
Principal Investigator
Department of Anaesthesia, McGill University Health Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials